EP 3145518 A1 20170329 - A COMPOSITION FOR USE IN TREATING OR PREVENTING VIRAL OR BACTERIAL INFECTIONS IN A SUBJECT UNDERGOING ANTI-TUMOR CHEMOTHERAPY, LEUKEMIA TREATMENT OR AIDS THERAPY COMPRISING L. REUTERI LER03 AND/OR L. SALIVARIUS LS06.
Title (en)
A COMPOSITION FOR USE IN TREATING OR PREVENTING VIRAL OR BACTERIAL INFECTIONS IN A SUBJECT UNDERGOING ANTI-TUMOR CHEMOTHERAPY, LEUKEMIA TREATMENT OR AIDS THERAPY COMPRISING L. REUTERI LER03 AND/OR L. SALIVARIUS LS06.
Title (de)
ZUSAMMENSETZUNG ZUR VERWENDUNG BEI DER BEHANDLUNG ODER PRÄVENTION VON VIRALEN ODER BAKTERIELLEN INFEKTIONEN IN EINEM PATIENTEN, ANTITUMOR-CHEMOTHERAPIE, LEUKÄMIEBEHANDLUNG ODER AIDS-THERAPIE MIT L. REUTERI LER03 UND/ODER L. SULIVARIUS LS06
Title (fr)
COMPOSITION COMPRENANT L. REUTERI LER03 ET/OU L. SALIVARIUS LS06, UTILISABLE DANS LE TRAITEMENT OU LA PRÉVENTION D'INFECTIONS VIRALES OU BACTÉRIENNES CHEZ UN SUJET SOUMIS À UNE CHIMIOTHÉRAPIE ANTICANCÉREUSE, UN TRAITEMENT DE LA LEUCÉMIE OU UNE THÉRAPIE CONTRE LE SIDA
Publication
Application
Priority
- IT MI20140815 A 20140505
- IB 2015000614 W 20150430
Abstract (en)
[origin: WO2015170159A1] The present invention relates to a composition for use as adjunctive therapy to antitumor chemotherapeutic treatments, acquired immunodeficiency syndrome treatments and leukemia treatments. The composition consists of a mixture comprising or, preferably, consisting of a strain of bacteria Lactobacillus reuteri LRE 03 DSM 23879 which is able to strongly stimulate the production of pro¬ inflammatory cytokines (Th1) interferon INF-gamma, said cytokines exhibit a marked antiviral and/or antibacterial activity, and/or a bacterial strain Lactobacillus salivanus LS06 DSM 26037 which is able to strongly stimulate the dendritic cell production, dendritic cells exhibit a marked antiviral and/or antibacterial activity. Furthermore, said composition can comprise one or more of the following compounds: a bacterial strain being able to produce, when ingested, bacterial exopolysaccharides EPS; and/or a plant polysaccharide such as tara gum; and/or an Aloe arborescens gel; and/or a gelling agent such as sodium alginate and/or a highly bioavailable zinc internalized into a tyndallized bacterial cell.
IPC 8 full level
A61K 35/74 (2015.01); A61P 31/04 (2006.01); A61P 31/12 (2006.01)
CPC (source: CN EP KR RU US)
A61K 9/06 (2013.01 - CN KR US); A61K 31/715 (2013.01 - CN); A61K 31/734 (2013.01 - CN); A61K 35/74 (2013.01 - EP KR RU US); A61K 35/744 (2013.01 - CN US); A61K 35/745 (2013.01 - CN US); A61K 35/747 (2013.01 - CN KR US); A61K 36/886 (2013.01 - CN KR); A61K 36/896 (2013.01 - CN); A61K 47/36 (2013.01 - CN); A61K 47/46 (2013.01 - CN); A61P 1/00 (2017.12 - EP); A61P 1/04 (2017.12 - EP); A61P 31/04 (2017.12 - EP RU); A61P 31/12 (2017.12 - EP RU); A61P 31/18 (2017.12 - EP); A61P 35/00 (2017.12 - EP); A61P 35/02 (2017.12 - EP); A61P 43/00 (2017.12 - EP)
Citation (search report)
See references of WO 2015170159A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2015170159 A1 20151112; WO 2015170159 A8 20161201; BR 112016024860 A2 20171017; CA 2946464 A1 20151112; CN 106573022 A 20170419; CN 111789871 A 20201020; EP 3145518 A1 20170329; EP 3145518 B1 20210217; JP 2017514862 A 20170608; JP 2020193207 A 20201203; JP 6817070 B2 20210120; KR 20160144501 A 20161216; RU 2016143921 A 20180605; RU 2016143921 A3 20181218; RU 2713414 C2 20200205; US 11077153 B2 20210803; US 2017112883 A1 20170427
DOCDB simple family (application)
IB 2015000614 W 20150430; BR 112016024860 A 20150430; CA 2946464 A 20150430; CN 201580024004 A 20150430; CN 202010065424 A 20150430; EP 15726675 A 20150430; JP 2016566716 A 20150430; JP 2020135085 A 20200807; KR 20167033184 A 20150430; RU 2016143921 A 20150430; US 201515307757 A 20150430